Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports
The MTB review of PGPV is clinically valuable, identifying PGPV in 12% of patients undergoing tumor NGS and a GCR of 42.5%. Rates of GC/GT completion were relatively low due to under-referral by treating physicians. Given the high GCR, the authors encourage institutional algorithms to help increase GC/GT rates for patients found to have PGPV following tumor NGS testing.
Authors
- Donglin Yan (ORCID: https://orcid.org/0000-0002-5111-9437)
- James P. Collard (ORCID: https://orcid.org/0000-0003-4930-7188)
- Rachel W. Miller (ORCID: https://orcid.org/0000-0002-9417-6642)
- Taylor Rives (ORCID: https://orcid.org/0000-0003-1084-6678)
- Jill Kolesar
- Justine Pickarski
- Frederick R. Ueland (ORCID: https://orcid.org/0000-0003-1213-7509)
- Ning Li (ORCID: https://orcid.org/0000-0002-9383-7381)
- Charles S. Dietrich
Institutions
- University of Kentucky (US)
- Markey Cancer Center (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1200/po.24.00301
- Citations
- 4
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.14
Funders
- Eli Lilly and Company
- National Institutes of Health
- National Cancer Institute